Product pipeline

Our medicines and vaccines in development are classified into three stages: Phase I, Phase II and Phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval. This page provides an outline of the medicines and vaccines in development.

The content of our development pipeline will change over time as new compounds progress from discovery to development and from development to the market. This annual pipeline information was published in March 2014. An update is expected to be available in March 2015.

Owing to the nature of the drug development, many compounds - especially those in early stages of investigation -  may be terminated through the development process. For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.

Brand names appearing in italics are trademarks either owned by and/or licensed to GSK or associated companies.

View the product pipeline by :-

Compound/ vaccine Type Indication Phase
Achieved Regulatory Review Milestones
MAA NDA/BLA
Antigen-specific cancer immunotherapeutic (ASCI)
MAGE-A3 immunotherapeutic† recombinant treatment of bladder cancer Phase II    
PRAME immunotherapeutic† recombinant treatment of resectable non-small cell lung cancer Phase II    
WT1 immunotherapeutic recombinant treatment of breast cancer Phase II    
MAGE-A3 immunotherapeutic† recombinant treatment of melanoma Phase III    
MAGE-A3 immunotherapeutic† recombinant treatment of non-small cell lung cancer Phase III    
Cardiovascular & metabolic
1278863 prolyl hydroxylase inhibitor (topical) wound healing Phase I    
2881078 selective androgen receptor modulator heart failure Phase I    
1278863 prolyl hydroxylase inhibitor anaemia associated with chronic renal disease & peri-operative risk reduction Phase II    
2330672 ileal bile acid transport inhibitor type 2 diabetes Phase II    
camicinal motilin receptor agonist delayed gastric emptying Phase II    
losmapimod p38 kinase inhibitor acute coronary syndrome (also COPD) Phase II    
retosiban oxytocin antagonist threatened pre-term labour Phase II    
darapladib Lp-PLA2 inhibitor atherosclerosis (also diabetic macular oedema) Phase III    
Eperzan (albiglutide) GLP 1 agonist type 2 diabetes Submitted PO: Jan14 S: Jan13
Dermatology (Stiefel)
1940029 stearoyl CoA desaturase 1 inhibitor (topical) acne vulgaris Phase I    
umeclidinium muscarinic acetylcholine antagonist (topical) hyperhidrosis (also COPD) Phase I    
2586184† Janus kinase 1 (JAK1) inhibitor psoriasis (also lupus) Phase II    
2894512† non-steroidal anti-inflammatory atopic dermatitis and psoriasis Phase II    
ofatumumab† CD20 human monoclonal antibody (s.c.) pemphigus vulgaris (also multiple sclerosis) Phase II    
Toctino (alitretinoin)† retinoic acid receptor modulator chronic hand eczema Phase III N/A  
Duac low dose clindamycin/benzoyl peroxide gel acne vulgaris Approved A: Mar13 N/A
HIV (ViiV Healthcare)
2838232 antiviral maturation inhibitor HIV infections Phase I    
1265744 HIV integrase inhibitor (long-acting parenteral formulation) HIV infections Phase II    
dolutegravir + abacavir sulphate+ lamivudine HIV integrase inhibitor + reverse transcriptaseinhibitors (fixed dose combination) HIV infections Submitted S: Oct13 S: Oct13
Tivicay (dolutegravir) HIV integrase inhibitor HIV infections Approved A: Jan14 A: Aug13
Immuno-inflammation
2586184† Janus kinase 1 (JAK1) inhibitor ulcerative colitis Phase I    
2618960 IL7 receptor monoclonal antibody autoimmune disease Phase I    
3117391† macrophage targeted histone deacetylase inhibitor rheumatoid arthritis Phase I    
2586184† Janus kinase 1 (JAK1) inhibitor systemic lupus erythematosus (also psoriasis) Phase II    
3196165 (MOR103)† granulocyte macrophage colony-stimulating factor monoclonal antibody rheumatoid arthritis Phase II    
belimumab B lymphocyte stimulator monoclonal antibody (i.v.) transplant rejection (also myaesthenia gravis) Phase II    
Benlysta (belimumab) B lymphocyte stimulator monoclonal antibody (s.c.) systemic lupus erythematosus Phase III    
Benlysta (belimumab) B lymphocyte stimulator monoclonal antibody (i.v.) vasculitis Phase III    
sirukumab† IL6 human monoclonal antibody (s.c.) rheumatoid arthritis Phase III    
Infectious diseases
2878175 NS5B polymerase inhibitor hepatitis C Phase I    
1322322 polypeptide deformylase inhibitor bacterial infections Phase II    
2140944 type 2 topoisomerase inhibitor bacterial infections Phase II    
tafenoquine† 8-aminoquinoline Plasmodium vivax malaria Phase II    
Relenza i.v. (zanamivir)† neuraminidase inhibitor (i.v.) influenza Phase III    
Neurosciences
2647544 Lp-PLA2 inhibitor Alzheimer's disease Phase I    
239512 H3 receptor antagonist multiple sclerosis Phase II    
249320 myelin-associated glycoprotein monoclonal antibody stroke Phase II    
belimumab B lymphocyte stimulator monoclonal antibody (i.v.) myaesthenia gravis (also transplant rejection) Phase II    
ofatumumab† CD20 human monoclonal antibody (s.c.) multiple sclerosis (also pemphigus vulgaris) Phase II    
rilapladib Lp-PLA2 inhibitor Alzheimer’s disease Phase II    
Oncology
2110183 AKT protein kinase inhibitor multiple myeloma Phase I    
2256098 focal adhesion kinase inhibitor cancer Phase I    
2636771 phosphatidylinositol 3-kinase inhibitor cancer Phase I    
2849330 ErbB3 monoclonal antibody cancer Phase I    
3052230† fibroblast growth factor ligand trap cancer Phase I    
525762 bromodomain inhibitor NUT gene midline carcinoma Phase I    
Votrient (pazopanib) + MK-3475† multi-kinase angiogenesis inhibitor + PD-1 monoclonal antibody renal cell cancer Phase I    
afuresertib (2110183) AKT protein kinase inhibitor multiple myeloma Phase I    
trametinib† + 2141795 MEK1/2 inhibitor + AKT protein kinase inhibitor cancer Phase I    
Mekinist (trametinib)† + Tafinlar (dabrafenib) + panitumumab† MEK1/2 inhibitor + BRAF protein kinase inhibitor + human anti-EGFR monoclonal antibody colorectal cancer Phase II    
Revolade/Promacta (eltrombopag)† thrombopoietin receptor agonist acute myeloid leukaemia Phase II    
Revolade/Promacta (eltrombopag)† thrombopoietin receptor agonist aplastic anaemia Phase II    
Revolade/Promacta (eltrombopag)† thrombopoietin receptor agonist myelodysplastic syndromes Phase II    
Tafinlar (dabrafenib) BRaf protein kinase inhibitor non-small cell lung cancer Phase II    
afuresertib (2110183) AKT protein kinase inhibitor ovarian cancer Phase II    
foretinib† mesenchymal-epithelial transition factor (C-met) kinase inhibitor non-small cell lung cancer Phase II    
Arzerra (ofatumumab)† CD20 human monoclonal antibody follicular lymphoma (refractory & relapsed patients) Phase III    
Arzerra (ofatumumab)† CD20 human monoclonal antibody chronic lymphocytic leukaemia, use in relapsed patients Phase III    
Arzerra (ofatumumab)† CD20 human monoclonal antibody diffuse large B cell lymphoma (relapsed patients) Phase III    
Mekinist (trametinib)† + Tafinlar (dabrafenib) MEK1/2 inhibitor + BRaf protein kinase inhibitor metastatic melanoma, adjuvant therapy Phase III    
Tyverb/Tykerb (lapatinib) human epidermal growth factor receptor-2 (Her2) and epidermal growth factor receptor (EGFR) dual kinase inhibitor breast cancer, neo-adjuvant & adjuvant therapy Phase III    
Votrient (pazopanib) multi-kinase angiogenesis inhibitor renal cell cancer, adjuvant therapy Phase III    
Arzerra (ofatumumab)† CD20 human monoclonal antibody chronic lymphocytic leukaemia, first line therapy Submitted S: Oct13 S: Oct13
Votrient (pazopanib) multi-kinase angiogenesis inhibitor ovarian cancer, maintenance therapy Submitted S: Aug13  
Mekinist (trametinib)† MEK1/2 inhibitor metastatic melanoma Approved S: Feb13 A: May13
Mekinist (trametinib)† + Tafinlar (dabrafenib) MEK 1/2 inhibitor + BRaf protein kinase inhibitor metastatic melanoma Approved S: Feb13 A: Jan14
Revolade/Promacta(eltrombopag)† thrombopoietin receptor agonist hepatitis C induced thrombocytopaenia Approved A: Sep13 A: Nov12
Tafinlar (dabrafenib) BRaf protein kinase inhibitor metastatic melanoma Approved A: Aug13 A: May13
Tyverb/Tykerb (lapatinib) Her2 and EGFR dual kinase inhibitor metastatic breast cancer, in combination with trastuzumab Approved A: Jul13  
Ophthalmology
933776 beta amyloid monoclonal antibody geographic retinal atrophy Phase II    
darapladib Lp-PLA2 inhibitor diabetic macular oedema (also atherosclerosis) Phase II    
Other vaccines
HIV† recombinant HIV disease prophylaxis Phase I    
NTHi† recombinant non-typeable Haemophilus influenzae prophylaxis Phase I    
HIV† recombinant HIV disease immunotherapy Phase II    
Hepatitis C recombinant viral vector hepatitis C virus prophylaxis Phase II    
Tuberculosis† recombinant tuberculosis prophylaxis Phase II    
Zoster† recombinant Herpes Zoster prophylaxis Phase III    
Flu (pre-) pandemic H5N1 inactivated split - monovalent (Quebec) pre-pandemic & pandemic influenza prophylaxis Approved N/A A: Nov13
Flu vaccine inactivated split - quadrivalent seasonal influenza prophylaxis Approved A: Feb13 A: Dec12
Paediatric vaccines
RSV recombinant respiratory syncytial virus prophylaxis (maternal immunisation) Phase I    
RSV recombinant viral vector respiratory syncytial virus prophylaxis Phase I    
S. pneumoniae next generation† recombinant - conjugated Streptococcus pneumoniae disease prophylaxis Phase II    
MMR live attenuated measles, mumps, rubella prophylaxis Phase III A: Nov97  
Mosquirix (Malaria RTS,S) recombinant malaria prophylaxis (Plasmodium falciparum) Phase III   N/A
Nimenrix (MenACWY-TT) conjugated Neisseria meningitis groups A, C, W & Y disease prophylaxis Approved A: Apr12  
Rare diseases
2398852† SAP monoclonal antibody amyloidosis Phase I    
2696274† ex-vivo stem cell gene therapy metachromatic leukodystrophy Phase II    
2696275† ex-vivo stem cell gene therapy Wiscott-Aldrich syndrome Phase II    
ozanezumab neurite outgrowth inhibitor (NOGO-A) monoclonal antibody amyotrophic lateral sclerosis Phase II    
2696273† ex-vivo stem cell gene therapy adenosine deaminase severe combined immune deficiency(ADA-SCID) Phase III    
Volibris (ambrisentan)† endothelin A antagonist chronic thromboembolic pulmonary hypertension Phase III    
mepolizumab IL5 monoclonal antibody (s.c.) eosinophilic granulomatosis with polyangiitis (also severe asthma) Phase III    
Respiratory
2126458 phosphoinositide 3 kinase inhibitor idiopathic pulmonary fibrosis Phase I    
2256294 soluble epoxide hydrolase inhibitor COPD Phase I    
2269557 phosphoinositide 3 kinase inhibitor asthma + COPD Phase I    
2793660 cathepsin C inhibitor bronchiectasis Phase I    
2862277 tumour necrosis factor receptor-1 domain antibody acute lung injury Phase I    
danirixin (1325756) CXCR2 chemokine receptor antagonist COPD Phase I    
fluticasone furoate + vilanterol† + umeclidinium glucocorticoid agonist + long-acting beta2 agonist + muscarinic acetylcholine antagonist COPD Phase I    
2245035 toll-like receptor 7 agonist asthma Phase II    
2339345 sodium channel blocker cough Phase II    
2586881 recombinant human angiotensin converting enzyme 2 acute lung injury Phase II    
961081† muscarinic acetylcholine antagonist, beta2 agonist COPD Phase II    
fluticasone furoate + umeclidinium glucocorticoid agonist + muscarinic acetylcholine antagonist asthma Phase II    
losmapimod p38 kinase inhibitor (oral) COPD (also acute coronary syndrome) Phase II    
mepolizumab IL5 monoclonal antibody nasal polyposis Phase II    
Relvar/Breo Ellipta (vilanterol† + fluticasone furoate) long-acting beta2 agonist + glucocorticoid agonist COPD - mortality outcomes Phase III    
mepolizumab IL5 monoclonal antibody severe asthma (also eosinophilic granulomatosis with polyangiitis) Phase III    
vilanterol† long-acting beta2 agonist COPD Phase III    
Incruse Ellipta* muscarinic acetylcholine antagonist COPD (also hyperhidrosis) Submitted S: April13 S: April13
fluticasone furoate glucocorticoid agonist asthma Submitted   S: Oct13
Anoro Ellipta (umeclidinium + vilanterol†) muscarinic acetylcholine antagonist + long-acting beta2 agonist COPD Approved PO: Feb14 A: Dec13
Relvar/Breo Ellipta (vilanterol† + fluticasone furoate) long-acting beta2 agonist + glucocorticoid agonist COPD Approved A: Nov13 A: May13
Relvar/Breo Ellipta (vilanterol† + fluticasone furoate) long-acting beta2 agonist + glucocorticoid agonist asthma Approved A: Nov13  

Cautionary statement regarding forward-looking information

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this pipeline chart, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.